ReportWire

Tag: likely possibility

  • The Most Mysterious Cells in Our Bodies Don’t Belong to Us

    The Most Mysterious Cells in Our Bodies Don’t Belong to Us

    [ad_1]

    Some 24 years ago, Diana Bianchi peered into a microscope at a piece of human thyroid and saw something that instantly gave her goosebumps. The sample had come from a woman who was chromosomally XX. But through the lens, Bianchi saw the unmistakable glimmer of Y chromosomes—dozens and dozens of them. “Clearly,” Bianchi told me, “part of her thyroid was entirely male.”

    The reason, Bianchi suspected, was pregnancy. Years ago, the patient had carried a male embryo, whose cells had at some point wandered out of the womb. They’d ended up in his mother’s thyroid—and, almost certainly, a bunch of other organs too—and taken on the identities and functions of the female cells that surrounded them so they could work in synchrony. Bianchi, now the director of the Eunice Kennedy Shriver National Institute of Child Health and Human Development, was astonished: “Her thyroid had been entirely remodeled by her son’s cells,” she said.

    The woman’s case wasn’t a one-off. Just about every time an embryo implants and begins to grow, it dispatches bits of itself into the body housing it. The depositions begin at least as early as four or five weeks into gestation. And they settle into just about every sliver of our anatomy where scientists have checked—the heart, the lungs, the breast, the colon, the kidney, the liver, the brain. From there, the cells might linger, grow, and divide for decades, or even, as many scientists suspect, for a lifetime, assimilating into the person that conceived them. They can almost be thought of as evolution’s original organ transplant, J. Lee Nelson, of the Fred Hutchinson Cancer Center in Seattle, told me. Microchimerism may be the most common way in which genetically identical cells mature and develop inside two bodies at once.

    These cross-generational transfers are bidirectional. As fetal cells cross the placenta into maternal tissues, a small number of maternal cells migrate into fetal tissues, where they can persist into adulthood. Genetic swaps, then, might occur several times throughout a life. Some researchers believe that people may be miniature mosaics of many of their relatives, via chains of pregnancy: their older siblings, perhaps, or their maternal grandmother, or any aunts and uncles their grandmother might have conceived before their mother was born. “It’s like you carry your entire family inside of you,” Francisco Úbeda de Torres, an evolutionary biologist at the Royal Holloway University of London, told me.

    All of that makes microchimerism—named in homage to the part-lion, part-goat, part-dragon chimera of Greek myth—more common than pregnancy itself. It’s thought to affect every person who has carried an embryo, even if briefly, and anyone who has ever inhabited a womb. Other mammals—mice, cows, dogs, our fellow primates—seem to haul around these cellular heirlooms too. But borrowed cells don’t always show up in the same spots, or in the same numbers. In many cases, microchimeric cells are thought to be present at concentrations on the order of one in 1 million—levels that, “for a lot of biological assays, is approaching or at the limit of detection,” Sing Sing Way, an immunologist and a pediatrician at Cincinnati Children’s Hospital, told me.

    Some scientists have argued that cells so sparse and inconsistent couldn’t possibly have meaningful effects. Even among microchimerism researchers, hypotheses about what these cells do—if anything at all—remain “highly controversial,” Way said. But many experts contend that microchimeric cells aren’t just passive passengers, adrift in someone else’s genomic sea. They are genetically distinct entities in a foreign residence, with their own evolutionary motivations that may clash with their landlord’s. And they might hold sway over many aspects of health: our susceptibility to infectious or autoimmune disease, the success of pregnancies, maybe even behavior. If these cells turn out to be as important as some scientists believe they are, they might be one of the most underappreciated architects of human life.

    Already, researchers have uncovered hints of what these wandering cells are up to. Way’s studies in mice, for instance, suggest that the microchimerism that babies inherit during gestation might help fine-tune their immune system, steeling the newborn body against viral infections; as the rodents age, their mother’s cells may aid in bringing their own pregnancies to term, by helping them see the fetus—made up of half-foreign DNA—as benign, rather than an unfamiliar threat.

    Similarly, inherited microchimerism might help explain why some studies have found that people are better at accepting organs from their mother than from their father, says William Burlingham, a transplant specialist at the University of Wisconsin at Madison. In the early ’90s, Burlingham treated a kidney-transplant patient who had abruptly stopped taking his immunosuppressive medications—a move that should have prompted his body’s rejection of the new organ. But “he was doing fine,” Burlingham told me. The patient’s kidney had come from his mother, whose cells were still circulating in his blood and skin; when his body encountered the transplanted tissues, it saw the newcomers as more of the same.

    Even fetal cells that meander into mothers during pregnancy might buoy the baby’s health. David Haig, an evolutionary biologist at Harvard, thinks that these cells may position themselves to optimally extract resources from Mom: in the brain, to command more attention; in the breast, to stimulate more milk production; in the thyroid, to coax more body heat. The cells, he told me, might also fiddle with a mother’s fertility, extending the interval between births to give the baby more uninterrupted care. Fetal delegates could then serve as informants for future offspring that inhabit the same womb, Úbeda de Torres told me. If later fetuses don’t detect much relatedness between themselves and their older siblings, he said, they might become greedier when siphoning nutrients from their mother’s body, rather than leaving extra behind for future siblings whose paternity may also differ from theirs.

    The perks of microchimerism for mothers have been tougher to pin down. One likely possibility is that the more thoroughly embryonic cells infiltrate the mother’s body, the better she might be able to tolerate her fetus’s tissue, reducing her chances of miscarriage or a high-risk birth. “I really think it’s a baby’s insurance policy on the mom,” Amy Boddy, a biological anthropologist at UC Santa Barbara, told me. “Like, ‘Hey, don’t attack.’” After delivery, the cells that stick around in the mother’s body may ease future pregnancies too (at least those by the same father). Pregnancy complications such as preeclampsia become rarer the more times someone conceives with the same partner. And when mothers send cellular envoys into their babies, they might be able to cut Mom a break by upping a child’s sleepiness, or curbing their fussiness.

    Microchimerism may not always be kind to moms. Nelson and others have found that, long-term, women with more fetal cells are also more likely to develop certain kinds of autoimmune disease, perhaps because their children’s cells are mistakenly reassessed by certain postpartum bodies as unwanted invaders. Nelson’s former postdoctoral fellow Nathalie Lambert, now at the French National Institute of Health and Medical Research, has found evidence in mouse experiments that fetal microchimeric cells may also produce antibodies that can goad attacks on maternal cells, Lambert told me. But the situation is also more complicated than that. “I don’t think they’re bad actors,” Nelson said of the interloping fetal cells. She and her colleagues have also found that fetal cells might sometimes protect against autoimmunity, leading a few conditions, such as rheumatoid arthritis, to actually abate during and shortly after pregnancy.

    In other contexts, too, fetal cells might offer both help and harm to the mother, or neither at all. Fetally derived microchimeric cells have been spotted voyaging into the cardiac tissues of mice who have experienced mid-pregnancy heart attacks, settling the pancreases of newly diabetic mouse moms, and lurking inside human tumors and C-section scars. But scientists aren’t sure whether the foreign cells are causing damage, repairing it, or simply bystanders, discovered in these spots by coincidence.

    These questions are so difficult to answer, Way told me, because microchimeric cells are so challenging to study. They might be in all of us, but they’re still rare, and frequently hidden in tough-to-access internal tissues. Researchers can’t yet say whether the cells actively deploy to predetermined sites or are pulled into specific organs by maternal cells—or just follow the natural flow of blood like river sediments. There’s also no consensus on how much microchimerism a body can tolerate. In a vacuum of evidence, even microchimerism researchers are steeling themselves for a letdown. “A very large part of me is prepared to think that most if not all microchimerism is completely benign,” Melissa Wilson, a computational evolutionary biologist at Arizona State University, told me.

    But if microchimeric cells do have a role to play in autoimmunity or reproductive success, the potential for therapies could be huge. One option, Burlingham told me, might be to infuse organ-transplant patients with cells from their mother, which could, like tiny ambassadors, coax the body into accepting any new tissue. Microchimerism-inspired therapies could help ease the burdens of high-risk pregnancies, Boddy told me, many of which seem to be fueled by the maternal body mounting an inappropriately aggressive immune response. They might also improve the experience of surrogates, who are more likely to experience pregnancy complications such as high blood pressure, preterm birth, and gestational diabetes. The cells’ stem-esque properties could even help researchers design better treatments for genetic diseases in utero; one research group, at UC San Francisco, is pursuing this idea for the blood disorder alpha thalassemia.

    Before those visions can be enacted, some questions need to be resolved. Researchers have unearthed evidence that microchimeric cells from different sources might sometimes compete with, or even displace one another, in bids for dominance. If the same dynamic plays out with future therapies, doctors may need to be careful about which cells they introduce to people and when, or risk losing the precious cargo they infuse. And, perhaps most fundamental, scientists can’t yet say how many microchimeric cells are necessary to exert influence over a specific person’s health—a threshold that will likely determine just how practical these theoretical treatments might be, Kristine Chua, a biological anthropologist at UCSB, told me.

    Even amid these uncertainties, the experts I spoke with stand by microchimerism’s likely importance: The cells are so persistent, so ubiquitous, so evolutionarily ancient, Boddy told me, that they must have an effect. The simple fact that they’re allowed to stick around for decades, while they grow and develop and change, could have a lot to teach us about immunity—and our understanding of ourselves. “In my mind, it does alter my concept of who I am,” Bianchi, who herself has given birth to a son, told me. Although he’s since grown up, she’s never without him, nor he without her.

    [ad_2]

    Katherine J. Wu

    Source link

  • How Bad Could BA.2.86 Get?

    How Bad Could BA.2.86 Get?

    [ad_1]

    Since Omicron swept across the globe in 2021, the evolution of SARS-CoV-2 has moved at a slower and more predictable pace. New variants of interest have come and gone, but none have matched Omicron’s 30-odd mutations or its ferocious growth. Then, about two weeks ago, a variant descended from BA.2 popped up with 34 mutations in its spike protein—a leap in viral evolution that sure looked a lot like Omicron. The question became: Could it also spread as quickly and as widely as Omicron?

    This new variant, dubbed BA.2.86, has now been detected in at least 15 cases across six countries, including Israel, Denmark, South Africa, and the United States. This is a trickle of new cases, not a flood, which is somewhat reassuring. But with COVID surveillance no longer a priority, the world’s labs are also sequencing about 1 percent of what they were two years ago, says Thomas Peacock, a virologist at the Pirbright Institute. The less surveillance scientists are doing, the more places a variant could spread out of sight, and the longer it will take to understand BA.2.86’s potential.

    Peacock told me that he will be closely tracking the data from Denmark in the next week or two. The country still has relatively robust SARS-CoV-2 sequencing, and because it has already detected BA.2.86, we can now watch the numbers rise—or not—in real time. Until the future of BA.2.86 becomes clear, three scenarios are still possible.

    The worst but also least likely scenario is another Omicron-like surge around the world. BA.2.86 just doesn’t seem to be growing as explosively. “If it had been very fast, we probably would have known by now,” Peacock said, noting that, in contrast, Omicron’s rapid growth took just three or four days to become obvious.

    Scientists aren’t totally willing to go on record ruling out Omicron redux yet, if only because patchy viral surveillance means no one has a complete global picture. Back in 2021, South Africa noticed that Omicron was driving a big COVID wave, which allowed its scientists to warn the rest of the world. But if BA.2.86 is now causing a wave in a region that isn’t sequencing viruses or even testing very much, no one would know.

    Even in this scenario, though, our collective immunity will be a buffer against the virus. BA.2.86 looks on paper to have Omicron-like abilities to cause reinfection, according to a preliminary analysis of its mutations by Jesse Bloom, a virologist at the Fred Hutchinson Cancer Center, in Washington, but he adds that there’s a big difference between 2021 and now. “At the time of the Omicron wave, there were still a lot of people out there that had never been either vaccinated or infected with SARS-CoV-2, and those people were sort of especially easy targets,” he told me. “Now the vast, vast majority of people in the world have either been infected or vaccinated with SARS-CoV-2—or are often both infected and vaccinated multiple times. So that means I think any variant is going to have a very hard time spreading as well as Omicron.”

    A second and more likely possibility is that BA.2.86 ends up like the other post-Omicron variants: transmissible enough to edge out a previous variant, but not transmissible enough to cause a big new surge. Since the original Omicron variant, or BA.1, took over, the U.S. has successively cycled through BA.2, BA.2.12.1, BA.5, BQ.1, XBB.1.5—and if these jumbles of numbers and letters seem only faintly familiar, it’s because they never reached the same levels of notoriety as the original. Vaccine makers track them to keep COVID shots up to date, but the World Health Organization hasn’t deemed any worthy of a new Greek letter.

    If BA.2.86 continues to circulate, though, it could pick up mutations that give it new advantages. In fact, XBB.1.5, which rose to dominance earlier this year, leveled up this way. When XBB.1.5’s predecessor was first identified in Singapore, Peacock said, it wasn’t a very successful variant: Its spike protein bound weakly to receptors in human cells. Then it acquired an additional mutation in its spike protein that compensated for the loss of binding, and it turned into the later-dominant XBB.1.5. Descendents of BA.2.86 could eventually become more transmissible than the variant looks right now.

    A third scenario is that BA.2.86 just fizzles out and goes away. Scientists now believe that highly mutated variants such as BA.2.86 are probably products of chronic infections in immunocompromised patients. In these infections, the virus remains in the body for a long time, trying out new ways to evade the immune system. It might end up with mutations that make its spike protein less recognizable to antibodies, but those same mutations could also render the spike protein less functional and therefore the virus less good at transmitting from person to person.

    “Variants like that have been identified over the last few years,” Bloom said. “Often there’s one sample found, and that’s it. Or multiple samples all found in the same place.” BA.2.86 is transmissible enough to be found multiple times in multiple places, but whether it can overtake existing variants is unclear. To do so, BA.2.86 needs to escape antibodies while also preserving its inherent transmissibility. Otherwise, Bloom said, cases might crop up here and there, but the variant never really takes off. In other words, the BA.2.86 situation basically stays where it is right now.

    The next few weeks will reveal which of these futures we’re living in. If the number of BA.2.86 cases starts to go up, in a way that requires more attention, we’ll know soon. But each week that the variant’s spread does not jump dramatically, the less likely BA.2.86 is to end up a variant of actual concern.

    [ad_2]

    Sarah Zhang

    Source link